View ValuationPharmX Technologies 将来の成長Future 基準チェック /06現在、 PharmX Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Software 収益成長26.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Feb 28First half 2026 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2025)First half 2026 results: AU$0.001 loss per share (further deteriorated from AU$0 in 1H 2025). Revenue: AU$3.89m (up 3.1% from 1H 2025). Net loss: AU$512.0k (down 430% from profit in 1H 2025). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 04PharmX Technologies Limited to Report First Half, 2026 Results on Feb 25, 2026PharmX Technologies Limited announced that they will report first half, 2026 results on Feb 25, 2026New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$7.5m revenue, or US$4.9m). Market cap is less than US$100m (AU$101.9m market cap, or US$66.8m).お知らせ • Sep 13PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025.お知らせ • Sep 01Pharmx Technologies Limited Announces Board Changes, Effective 1 September 2025PharmX Technologies Limited announced that Mr. Alexander (Sandy) Mellis has been appointed as a full Non-Executive Director of the Company with effect from1 September 2025, having resigned from his position as an Alternate Director to Mr. Dennis Bastas. Mr. Mellis has acted as an Alternate Director to Mr. Bastas since September 2024 and has provided invaluable contribution to the Board during this time. Mr. Mellis will continue to provide his 25+ years industry experience in consumer health brands and the Australian consumer goods market across a variety of market channels to the Company, having consented to a full position on the Board. Mr. Mellis has been appointed to fill a casual vacancy in accordance with the Company's Constitution until the Company's 2025 Annual General Meeting (AGM) whereby Mr. Mellis will stand for election in accordance with the Company's Constitution and ASX Listing Rules. The Company notes it was originally intended that Mr. Mellis remain as Alternate Director until the 2025 AGM where he was then due to step down as an Alternate Director and stand for election as a Non-Executive Director, however the Board (with Mr. Mellis' endorsement) has chosen to expedite the appoint of Mr. Mellis in light of the immediate resignation of Mr. Dennis Bastas. The Company has identified and acknowledges a breach of ASX Listing Rule 14.4 in relation to Mr. Bastas' current term as a Director of the Company. At the 2024 AGM, Pharmx had planned to seek re-election of Mr. Bastas as a Non-Executive Director in accordance with the requirements under its Constitution and the ASX's Listing Rules, however due to an administrative oversight from its 2024 AGM the resolution was omitted from the Notice of Meeting, resulting in Mr. Bastas continuing as a Director for a period longer than the 3-year term stipulated by the ASX Listing Rules without standing for re- election. Mr. Bastas, by mutual agreement with the Company, has resigned as a Director of the Company with effective from 1 September 2025, allowing him to focus more fully on his position as Chairman & Group CEO of DBG Health.Board Change • Aug 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 21Full year 2025 earnings released: AU$0.04 loss per share (vs AU$0 in FY 2024)Full year 2025 results: AU$0.04 loss per share (further deteriorated from AU$0 in FY 2024). Revenue: AU$7.53m (down 7.0% from FY 2024). Net loss: AU$264.0k (down 378% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 186 percentage points per year, which is a significant difference in performance.お知らせ • Aug 13PharmX Technologies Limited to Report Fiscal Year 2025 Results on Aug 20, 2025PharmX Technologies Limited announced that they will report fiscal year 2025 results on Aug 20, 2025Reported Earnings • Feb 21First half 2025 earnings released: EPS: AU$0 (vs AU$0 in 1H 2024)First half 2025 results: EPS: AU$0 (in line with 1H 2024). Revenue: AU$3.77m (up 17% from 1H 2024). Net income: AU$155.0k (down 34% from 1H 2024). Profit margin: 4.1% (down from 7.3% in 1H 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.New Risk • Feb 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 119% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (119% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.2% net profit margin). Market cap is less than US$100m (AU$50.3m market cap, or US$31.9m).お知らせ • Feb 03PharmX Technologies Limited to Report First Half, 2025 Results on Feb 19, 2025PharmX Technologies Limited announced that they will report first half, 2025 results on Feb 19, 2025New Risk • Jan 11New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: AU$8.1m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (AU$8.1m revenue, or US$5.0m). Market cap is less than US$100m (AU$46.1m market cap, or US$28.3m).お知らせ • Nov 28PharmX Technologies Limited Announces Change of Company SecretaryPharmX Technologies Limited announced the appointment of Christopher Fernandes as Company Secretary with effect from 27 November 2024, replacing Sally McDow. Mr. Fernandes is an employee of BoardRoom Pty Ltd. (the Company's Corporate Secretarial provider). Chris is an experienced Company Secretary with expertise in corporate governance functions of private and public companies in both Australia and the United Kingdom. For the purpose of ASX listing rule 12.6, Mr. Fernandes will be the person responsible for communications with the ASX in relation to ASX Listing Rule matters.お知らせ • Oct 25PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024. Location: bdo audit pty ltd at rooms 5 & 6, level 11, 1 margaret street, sydney nsw 2000, sydney Australiaお知らせ • Sep 11PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate DirectorPharmX Technologies Ltd. has announced a change to its Board of Directors, appointing Alexander (Sandy) Mellis as a Non-Executive and Independent Alternate Director for Mr. Dennis Bastas, effective immediately. Sandy Mellis brings over 25 years of experience in the consumer health and goods sectors, having developed and managed brands across Australia, New Zealand, the UK, the US, and Europe. His recent roles include serving as Chief Commercial Officer of DBG Health and Chief Executive Officer of VidaCorp, the Consumer Health & Beauty division of DBG Health.Reported Earnings • Aug 28Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)Full year 2024 results: EPS: AU$0 (improved from AU$0.001 loss in FY 2023). Revenue: AU$8.09m (up 32% from FY 2023). Net income: AU$95.0k (up AU$978.0k from FY 2023). Profit margin: 1.2% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.New Risk • Aug 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Revenue is less than US$5m (AU$6.3m revenue, or US$4.1m). Market cap is less than US$100m (AU$18.0m market cap, or US$11.8m).お知らせ • Jul 24PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024PharmX Technologies Limited announced that they will report fiscal year 2024 results on Aug 21, 2024Reported Earnings • Feb 24First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)First half 2024 results: EPS: AU$0 (improved from AU$0.001 loss in 1H 2023). Revenue: AU$3.24m (down 47% from 1H 2023). Net income: AU$236.0k (up AU$807.0k from 1H 2023). Profit margin: 7.3% (up from net loss in 1H 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.お知らせ • Feb 14PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024PharmX Technologies Limited announced that they will report first half, 2024 results on Feb 23, 2024Buy Or Sell Opportunity • Feb 13Now 27% overvaluedOver the last 90 days, the stock has fallen 37% to AU$0.029. The fair value is estimated to be AU$0.023, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 9.4% over the last 3 years. Meanwhile, the company became loss making.分析記事 • Feb 12What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?PharmX Technologies Limited ( ASX:PHX ), is not the largest company out there, but it received a lot of attention from...New Risk • Feb 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.0m (US$9.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Market cap is less than US$10m (AU$15.0m market cap, or US$9.76m). Minor Risk Revenue is less than US$5m (AU$6.1m revenue, or US$4.0m).New Risk • Jan 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$6.1m revenue, or US$4.0m). Market cap is less than US$100m (AU$21.5m market cap, or US$14.2m).お知らせ • Nov 17PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023The Board of PharmX Technologies Limited announced the appointment of Tom Culver as CEO effective 20th November 2023. Tom joins PharmX with an extensive background in leading innovative technology companies, driving sales and implementing growth strategies. He has over 20 years of experience as a founder and business owner, as well as in senior leadership roles in organizations across the public and private sectors in both B2B and consumer focused enterprises. His appointment comes as PharmX is poised for growth following significant recent investment in its EDI gateway and Marketplace capabilities. His technology, growth and leadership experience will be vital as the company focuses on revenue growth, delivering exceptional customer engagement, and raising its profile with enterprise providers and pharmacists across Australia and New Zealand. Nick England will revert to his role as non-executive Chairman after a brief transition period.お知らせ • Oct 20PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023, at 11:01 AUS Eastern Standard Time. Location: Suite 11.02, Level 11, 17 Castlereagh Street Sydney New South Wales Australia Agenda: To consider and approve the Financial Statements, Directors' Report and Auditor's Report of the Company for the year ended 30 June 2023; to consider and approve election of Directors; to consider and approve remuneration report; to consider and approve of Additional 10% Placement Facility.New Risk • Sep 01New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 7.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Minor Risks Revenue is less than US$5m (AU$6.1m revenue, or US$3.9m). Market cap is less than US$100m (AU$23.9m market cap, or US$15.4m).Reported Earnings • Aug 24Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)Full year 2023 results: AU$0.002 loss per share (further deteriorated from AU$0 in FY 2022). Revenue: AU$6.13m (down 49% from FY 2022). Net loss: AU$883.0k (down AU$901.0k from profit in FY 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance.お知らせ • Aug 18Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023Corum Group Limited announced that they will report fiscal year 2023 results on Aug 23, 2023お知らせ • Jul 23Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million on July 21, 2023. The purchase price of AUD 6.25 million, on a cash free and debt free basis and subject to working capital adjustments, comprises of an initial purchase amount of AUD 4.75 million and a deferred purchase amount of AUD 1.5 million (payable on the first anniversary of completion, subject to any price adjustment for working capital adjustments or warranty claims). The purchase price may be increased through the achievement of annual recurring revenue targets (earnout payments) based on the achievement of certain business metrics on the first and second anniversaries of completion. Completion of the sale is subject to shareholder approval.分析記事 • Jul 12A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)Key Insights The projected fair value for Corum Group is AU$0.046 based on 2 Stage Free Cash Flow to Equity Current...分析記事 • May 11At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?Corum Group Limited ( ASX:COO ), might not be a large cap stock, but it saw a significant share price rise of over 20...Reported Earnings • Feb 25First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)First half 2023 results: AU$0.001 loss per share (further deteriorated from AU$0 in 1H 2022). Revenue: AU$6.12m (flat on 1H 2022). Net loss: AU$571.0k (down AU$659.0k from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 13Corum Group Limited, Annual General Meeting, Nov 14, 2022Corum Group Limited, Annual General Meeting, Nov 14, 2022.Reported Earnings • Aug 31Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)Full year 2022 results: EPS: AU$0 (down from AU$0.002 in FY 2021). Revenue: AU$12.0m (down 11% from FY 2021). Net income: AU$18.0k (down 98% from FY 2021). Profit margin: 0.2% (down from 8.2% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 22Corum Group Limited Launches Pharmxchange PlatformCorum Group Limited announced the launch of the PharmXchange platform. PharmXchange offers a feature rich tailored digital sales and marketing solution available for use by all pharmacies catering for a wide range of supplier use cases. Key features of PharmXchange include: Tailored digital sales and marketing options for brands and products; PharmX compliant electronic invoicing with direct ordering option where POS ordering not available; Promotion options to coordinate with supplier requirements; Education centre for centralised availability of supplier knowledge base content; PharmXpay integrated payments solution delivered in partnership with specialist payments processorZenith Payments; Suppliers access to electronic transactions without the need for full PharmX integration; Improved pharmacy efficiency through reduced requirement for manual order and invoice. PharmXchange is now live in pilot phase with a concentrated group of pharmacies and suppliers ahead of an anticipated near term full commercial launch. Corum will update the market in due course on revenue estimates.Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Mar 29Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million on December 18, 2021. Transaction is expected to be completed in Q1 of the 2022 calendar year. Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) on March 29, 2022.Reported Earnings • Feb 11First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: EPS: AU$0 (down from AU$0.002 in 1H 2021). Revenue: AU$6.10m (up 4.1% from 1H 2021). Net income: AU$88.0k (down 91% from 1H 2021). Profit margin: 1.4% (down from 17% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) were also behind analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 32% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 04Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022Corum Group Limited announced that they will report first half, 2022 results on Feb 10, 2022お知らせ • Feb 01+ 1 more updateCorum Group Limited Announces Resignation of Julian Sallabank as Managing DirectorCorum Group Limited announced that Julian Sallabank has tendered his resignation as CEO and Managing Director effective immediately and the Board has accepted. Julian will be resuming his previous position as Managing Director of the Tegmen Fund. Chairman Nick England will step in as interim CEO effective immediately, assuming the position of Executive Chairman whilst a comprehensive search commences for a permanent replacement. Nick joined the Corum Board in September 2019 and was elected Chairman in February 2020. He has over 35 years of senior operational experience in the healthcare industry both in Australia and internationally.お知らせ • Dec 21Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million on December 18, 2021. Transaction is expected to be completed in Q1 of the 2022 calendar year.分析記事 • Nov 12Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Reported Earnings • Aug 22Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$13.4m (up 26% from FY 2020). Net income: AU$1.09m (up AU$915.0k from FY 2020). Profit margin: 8.2% (up from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.分析記事 • Apr 29At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?Corum Group Limited ( ASX:COO ), might not be a large cap stock, but it saw a decent share price growth in the teens...分析記事 • Mar 02Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good NewsDespite posting strong earnings, Corum Group Limited's ( ASX:COO ) stock didn't move much over the last week. We looked...Reported Earnings • Feb 26First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$6.64m (up 33% from 1H 2020). Net income: AU$988.0k (up AU$1.29m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 17Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021Corum Group Limited announced that they will report first half, 2021 results on Feb 24, 2021分析記事 • Dec 13Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?Corum Group's (ASX:COO) stock is up by a considerable 96% over the past three months. But the company's key financial...お知らせ • Nov 06+ 1 more updateCorum Group Limited Announces Appointment of Dennis Bastas to the Board of DirectorsCorum Group Limited announced that an agreement has been executed with Arrotex Pharmaceuticals to become a strategic shareholder in Corum. As part of the transaction Arrotex Executive Chairman Dennis Bastas will be invited and has undertaken to join the Corum Board following completion of the share placement and after the upcoming 2020 Corum Annual General Meeting.お知らせ • Nov 03Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020Corum Group Limited announced the appointment of Ms. Eryl Baron as company secretary, effective 3 November 2020. Ms. Baron replaces Mr. Julian Rockett who has been company secretary since 31 August 2020.お知らせ • Oct 15Corum Group Limited Appoints Jayne Shaw to its Board of DirectorsCorum Group Ltd. announced that Jayne Shaw has accepted an appointment to the Corum Group's Board of Directors. Jayne has significant experience in healthcare management and an experienced clinical background in nursing. Jayne has been a member of a number of private healthcare boards involved with specialist consolidation including cardiology, cancer care, orthopaedics, and women's health and has worked extensively with private equity firms on local and International Healthcare transactions.お知らせ • Sep 05Corum Group Limited (ASX:COO) completed the acquisition of remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty. Ltd. and Daleflag Pty Ltd.Corum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 million on September 1, 2020. Under the terms of consideration, Corum Group Limited will pay AUD 3.75 million on completion and balance of deferred consideration of AUD 4.15 million to be paid on or before 15 October 2020. Post Completion of the acquisition PharmX will continue to operate as an independent business within the Corum Group in line with its all of market focus. Corum Group launched pro-rata entitlement offer of 1 new Share for every 3 Shares at price of AUD 0.042 per share to raise AUD 5.6 million on September 1, 2020. The proceeds of the Entitlement Offer will be used to partially fund acquisition of the remaining equity and units in PharmX Pty Ltd. Transaction is expected to complete on or before September 4, 2020. The Corum Board expects the acquisition to be earnings per share accretive in its first year. Positive operating cashflow quarterly run rate into FY’21 with acquisition of remaining 57% PharmX interest to further assist. Corum Group Limited (ASX:COO) completed the acquisition of remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty. Ltd. and Daleflag Pty Ltd on September 4, 2020.お知らせ • Sep 01+ 1 more updateCorum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 millionCorum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 million on September 1, 2020. Under the terms of consideration, Corum Group Limited will pay AUD 3.75 million on completion and balance of deferred consideration of AUD 4.15 million to be paid on or before 15 October 2020. Post Completion of the acquisition PharmX will continue to operate as an independent business within the Corum Group in line with its all of market focus. Corum Group launched pro-rata entitlement offer of 1 new Share for every 3 Shares at price of AUD 0.042 per share to raise AUD 5.6 million on September 1, 2020. The proceeds of the Entitlement Offer will be used to partially fund acquisition of the remaining equity and units in PharmX Pty Ltd. Transaction is expected to complete on or before September 4, 2020. The Corum Board expects the acquisition to be earnings per share accretive in its first year. Positive operating cashflow quarterly run rate into FY’21 with acquisition of remaining 57% PharmX interest to further assist.お知らせ • Aug 27Corum Group Limited (ASX:COO) completed the acquisition of an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd.Corum Group Limited (ASX:COO) entered into an agreement to acquire an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd for AUD 0.77 million on March 24, 2020. The transaction is expected to be accretive in the first year. Corum Group Limited (ASX:COO) completed the acquisition of an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd on March 31, 2020. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PharmX Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ASX:PHX - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20258-1-11N/A9/30/20258-1-5-4N/A6/30/202580-10-8N/A3/31/202580-9-8N/A12/31/202490-9-8N/A9/30/202480-4-2N/A6/30/20248023N/A3/31/20247057N/A12/31/202360911N/A9/30/202360811N/A6/30/20236-1811N/A12/31/20222-1-13N/A9/30/20224-1-13N/A6/30/202250-13N/A3/31/2022120-13N/A12/31/2021120-13N/A9/30/2021121-13N/A6/30/2021121-13N/A3/31/2021121-13N/A12/31/2020111-12N/A9/30/2020111-21N/A6/30/2020110-30N/A3/31/202011-1-30N/A12/31/201910-2-30N/A9/30/201911-3N/A1N/A6/30/201911-4N/A1N/A3/31/201912-3N/A2N/A12/31/201812-2N/A3N/A9/30/201812-1N/A1N/A6/30/2018130N/A0N/A3/31/201813-3N/A0N/A12/31/201714-6N/A0N/A9/30/201714-6N/A0N/A6/30/201715-6N/A0N/A3/31/201715-3N/A-1N/A12/31/2016161N/A-1N/A9/30/2016160N/A-1N/A6/30/2016170N/A-1N/A3/31/2016171N/AN/AN/A12/31/2015171N/A2N/A9/30/2015183N/A3N/A6/30/2015185N/A4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PHXの予測収益成長が 貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PHXの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PHXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PHXの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PHXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PHXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSoftware 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 01:25終値2026/05/20 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PharmX Technologies Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Caleb WengPAC Partners Securities Pty. Ltd.
Reported Earnings • Feb 28First half 2026 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2025)First half 2026 results: AU$0.001 loss per share (further deteriorated from AU$0 in 1H 2025). Revenue: AU$3.89m (up 3.1% from 1H 2025). Net loss: AU$512.0k (down 430% from profit in 1H 2025). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 04PharmX Technologies Limited to Report First Half, 2026 Results on Feb 25, 2026PharmX Technologies Limited announced that they will report first half, 2026 results on Feb 25, 2026
New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$7.5m revenue, or US$4.9m). Market cap is less than US$100m (AU$101.9m market cap, or US$66.8m).
お知らせ • Sep 13PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025.
お知らせ • Sep 01Pharmx Technologies Limited Announces Board Changes, Effective 1 September 2025PharmX Technologies Limited announced that Mr. Alexander (Sandy) Mellis has been appointed as a full Non-Executive Director of the Company with effect from1 September 2025, having resigned from his position as an Alternate Director to Mr. Dennis Bastas. Mr. Mellis has acted as an Alternate Director to Mr. Bastas since September 2024 and has provided invaluable contribution to the Board during this time. Mr. Mellis will continue to provide his 25+ years industry experience in consumer health brands and the Australian consumer goods market across a variety of market channels to the Company, having consented to a full position on the Board. Mr. Mellis has been appointed to fill a casual vacancy in accordance with the Company's Constitution until the Company's 2025 Annual General Meeting (AGM) whereby Mr. Mellis will stand for election in accordance with the Company's Constitution and ASX Listing Rules. The Company notes it was originally intended that Mr. Mellis remain as Alternate Director until the 2025 AGM where he was then due to step down as an Alternate Director and stand for election as a Non-Executive Director, however the Board (with Mr. Mellis' endorsement) has chosen to expedite the appoint of Mr. Mellis in light of the immediate resignation of Mr. Dennis Bastas. The Company has identified and acknowledges a breach of ASX Listing Rule 14.4 in relation to Mr. Bastas' current term as a Director of the Company. At the 2024 AGM, Pharmx had planned to seek re-election of Mr. Bastas as a Non-Executive Director in accordance with the requirements under its Constitution and the ASX's Listing Rules, however due to an administrative oversight from its 2024 AGM the resolution was omitted from the Notice of Meeting, resulting in Mr. Bastas continuing as a Director for a period longer than the 3-year term stipulated by the ASX Listing Rules without standing for re- election. Mr. Bastas, by mutual agreement with the Company, has resigned as a Director of the Company with effective from 1 September 2025, allowing him to focus more fully on his position as Chairman & Group CEO of DBG Health.
Board Change • Aug 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 21Full year 2025 earnings released: AU$0.04 loss per share (vs AU$0 in FY 2024)Full year 2025 results: AU$0.04 loss per share (further deteriorated from AU$0 in FY 2024). Revenue: AU$7.53m (down 7.0% from FY 2024). Net loss: AU$264.0k (down 378% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 186 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 13PharmX Technologies Limited to Report Fiscal Year 2025 Results on Aug 20, 2025PharmX Technologies Limited announced that they will report fiscal year 2025 results on Aug 20, 2025
Reported Earnings • Feb 21First half 2025 earnings released: EPS: AU$0 (vs AU$0 in 1H 2024)First half 2025 results: EPS: AU$0 (in line with 1H 2024). Revenue: AU$3.77m (up 17% from 1H 2024). Net income: AU$155.0k (down 34% from 1H 2024). Profit margin: 4.1% (down from 7.3% in 1H 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
New Risk • Feb 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 119% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (119% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.2% net profit margin). Market cap is less than US$100m (AU$50.3m market cap, or US$31.9m).
お知らせ • Feb 03PharmX Technologies Limited to Report First Half, 2025 Results on Feb 19, 2025PharmX Technologies Limited announced that they will report first half, 2025 results on Feb 19, 2025
New Risk • Jan 11New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: AU$8.1m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (AU$8.1m revenue, or US$5.0m). Market cap is less than US$100m (AU$46.1m market cap, or US$28.3m).
お知らせ • Nov 28PharmX Technologies Limited Announces Change of Company SecretaryPharmX Technologies Limited announced the appointment of Christopher Fernandes as Company Secretary with effect from 27 November 2024, replacing Sally McDow. Mr. Fernandes is an employee of BoardRoom Pty Ltd. (the Company's Corporate Secretarial provider). Chris is an experienced Company Secretary with expertise in corporate governance functions of private and public companies in both Australia and the United Kingdom. For the purpose of ASX listing rule 12.6, Mr. Fernandes will be the person responsible for communications with the ASX in relation to ASX Listing Rule matters.
お知らせ • Oct 25PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024. Location: bdo audit pty ltd at rooms 5 & 6, level 11, 1 margaret street, sydney nsw 2000, sydney Australia
お知らせ • Sep 11PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate DirectorPharmX Technologies Ltd. has announced a change to its Board of Directors, appointing Alexander (Sandy) Mellis as a Non-Executive and Independent Alternate Director for Mr. Dennis Bastas, effective immediately. Sandy Mellis brings over 25 years of experience in the consumer health and goods sectors, having developed and managed brands across Australia, New Zealand, the UK, the US, and Europe. His recent roles include serving as Chief Commercial Officer of DBG Health and Chief Executive Officer of VidaCorp, the Consumer Health & Beauty division of DBG Health.
Reported Earnings • Aug 28Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)Full year 2024 results: EPS: AU$0 (improved from AU$0.001 loss in FY 2023). Revenue: AU$8.09m (up 32% from FY 2023). Net income: AU$95.0k (up AU$978.0k from FY 2023). Profit margin: 1.2% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
New Risk • Aug 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Revenue is less than US$5m (AU$6.3m revenue, or US$4.1m). Market cap is less than US$100m (AU$18.0m market cap, or US$11.8m).
お知らせ • Jul 24PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024PharmX Technologies Limited announced that they will report fiscal year 2024 results on Aug 21, 2024
Reported Earnings • Feb 24First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)First half 2024 results: EPS: AU$0 (improved from AU$0.001 loss in 1H 2023). Revenue: AU$3.24m (down 47% from 1H 2023). Net income: AU$236.0k (up AU$807.0k from 1H 2023). Profit margin: 7.3% (up from net loss in 1H 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 14PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024PharmX Technologies Limited announced that they will report first half, 2024 results on Feb 23, 2024
Buy Or Sell Opportunity • Feb 13Now 27% overvaluedOver the last 90 days, the stock has fallen 37% to AU$0.029. The fair value is estimated to be AU$0.023, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 9.4% over the last 3 years. Meanwhile, the company became loss making.
分析記事 • Feb 12What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?PharmX Technologies Limited ( ASX:PHX ), is not the largest company out there, but it received a lot of attention from...
New Risk • Feb 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.0m (US$9.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Market cap is less than US$10m (AU$15.0m market cap, or US$9.76m). Minor Risk Revenue is less than US$5m (AU$6.1m revenue, or US$4.0m).
New Risk • Jan 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$6.1m revenue, or US$4.0m). Market cap is less than US$100m (AU$21.5m market cap, or US$14.2m).
お知らせ • Nov 17PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023The Board of PharmX Technologies Limited announced the appointment of Tom Culver as CEO effective 20th November 2023. Tom joins PharmX with an extensive background in leading innovative technology companies, driving sales and implementing growth strategies. He has over 20 years of experience as a founder and business owner, as well as in senior leadership roles in organizations across the public and private sectors in both B2B and consumer focused enterprises. His appointment comes as PharmX is poised for growth following significant recent investment in its EDI gateway and Marketplace capabilities. His technology, growth and leadership experience will be vital as the company focuses on revenue growth, delivering exceptional customer engagement, and raising its profile with enterprise providers and pharmacists across Australia and New Zealand. Nick England will revert to his role as non-executive Chairman after a brief transition period.
お知らせ • Oct 20PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023, at 11:01 AUS Eastern Standard Time. Location: Suite 11.02, Level 11, 17 Castlereagh Street Sydney New South Wales Australia Agenda: To consider and approve the Financial Statements, Directors' Report and Auditor's Report of the Company for the year ended 30 June 2023; to consider and approve election of Directors; to consider and approve remuneration report; to consider and approve of Additional 10% Placement Facility.
New Risk • Sep 01New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 7.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Minor Risks Revenue is less than US$5m (AU$6.1m revenue, or US$3.9m). Market cap is less than US$100m (AU$23.9m market cap, or US$15.4m).
Reported Earnings • Aug 24Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)Full year 2023 results: AU$0.002 loss per share (further deteriorated from AU$0 in FY 2022). Revenue: AU$6.13m (down 49% from FY 2022). Net loss: AU$883.0k (down AU$901.0k from profit in FY 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 18Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023Corum Group Limited announced that they will report fiscal year 2023 results on Aug 23, 2023
お知らせ • Jul 23Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million on July 21, 2023. The purchase price of AUD 6.25 million, on a cash free and debt free basis and subject to working capital adjustments, comprises of an initial purchase amount of AUD 4.75 million and a deferred purchase amount of AUD 1.5 million (payable on the first anniversary of completion, subject to any price adjustment for working capital adjustments or warranty claims). The purchase price may be increased through the achievement of annual recurring revenue targets (earnout payments) based on the achievement of certain business metrics on the first and second anniversaries of completion. Completion of the sale is subject to shareholder approval.
分析記事 • Jul 12A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)Key Insights The projected fair value for Corum Group is AU$0.046 based on 2 Stage Free Cash Flow to Equity Current...
分析記事 • May 11At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?Corum Group Limited ( ASX:COO ), might not be a large cap stock, but it saw a significant share price rise of over 20...
Reported Earnings • Feb 25First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)First half 2023 results: AU$0.001 loss per share (further deteriorated from AU$0 in 1H 2022). Revenue: AU$6.12m (flat on 1H 2022). Net loss: AU$571.0k (down AU$659.0k from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 13Corum Group Limited, Annual General Meeting, Nov 14, 2022Corum Group Limited, Annual General Meeting, Nov 14, 2022.
Reported Earnings • Aug 31Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)Full year 2022 results: EPS: AU$0 (down from AU$0.002 in FY 2021). Revenue: AU$12.0m (down 11% from FY 2021). Net income: AU$18.0k (down 98% from FY 2021). Profit margin: 0.2% (down from 8.2% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 22Corum Group Limited Launches Pharmxchange PlatformCorum Group Limited announced the launch of the PharmXchange platform. PharmXchange offers a feature rich tailored digital sales and marketing solution available for use by all pharmacies catering for a wide range of supplier use cases. Key features of PharmXchange include: Tailored digital sales and marketing options for brands and products; PharmX compliant electronic invoicing with direct ordering option where POS ordering not available; Promotion options to coordinate with supplier requirements; Education centre for centralised availability of supplier knowledge base content; PharmXpay integrated payments solution delivered in partnership with specialist payments processorZenith Payments; Suppliers access to electronic transactions without the need for full PharmX integration; Improved pharmacy efficiency through reduced requirement for manual order and invoice. PharmXchange is now live in pilot phase with a concentrated group of pharmacies and suppliers ahead of an anticipated near term full commercial launch. Corum will update the market in due course on revenue estimates.
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Mar 29Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million on December 18, 2021. Transaction is expected to be completed in Q1 of the 2022 calendar year. Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) on March 29, 2022.
Reported Earnings • Feb 11First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: EPS: AU$0 (down from AU$0.002 in 1H 2021). Revenue: AU$6.10m (up 4.1% from 1H 2021). Net income: AU$88.0k (down 91% from 1H 2021). Profit margin: 1.4% (down from 17% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) were also behind analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 32% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 04Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022Corum Group Limited announced that they will report first half, 2022 results on Feb 10, 2022
お知らせ • Feb 01+ 1 more updateCorum Group Limited Announces Resignation of Julian Sallabank as Managing DirectorCorum Group Limited announced that Julian Sallabank has tendered his resignation as CEO and Managing Director effective immediately and the Board has accepted. Julian will be resuming his previous position as Managing Director of the Tegmen Fund. Chairman Nick England will step in as interim CEO effective immediately, assuming the position of Executive Chairman whilst a comprehensive search commences for a permanent replacement. Nick joined the Corum Board in September 2019 and was elected Chairman in February 2020. He has over 35 years of senior operational experience in the healthcare industry both in Australia and internationally.
お知らせ • Dec 21Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million on December 18, 2021. Transaction is expected to be completed in Q1 of the 2022 calendar year.
分析記事 • Nov 12Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Reported Earnings • Aug 22Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$13.4m (up 26% from FY 2020). Net income: AU$1.09m (up AU$915.0k from FY 2020). Profit margin: 8.2% (up from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
分析記事 • Apr 29At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?Corum Group Limited ( ASX:COO ), might not be a large cap stock, but it saw a decent share price growth in the teens...
分析記事 • Mar 02Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good NewsDespite posting strong earnings, Corum Group Limited's ( ASX:COO ) stock didn't move much over the last week. We looked...
Reported Earnings • Feb 26First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$6.64m (up 33% from 1H 2020). Net income: AU$988.0k (up AU$1.29m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 17Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021Corum Group Limited announced that they will report first half, 2021 results on Feb 24, 2021
分析記事 • Dec 13Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?Corum Group's (ASX:COO) stock is up by a considerable 96% over the past three months. But the company's key financial...
お知らせ • Nov 06+ 1 more updateCorum Group Limited Announces Appointment of Dennis Bastas to the Board of DirectorsCorum Group Limited announced that an agreement has been executed with Arrotex Pharmaceuticals to become a strategic shareholder in Corum. As part of the transaction Arrotex Executive Chairman Dennis Bastas will be invited and has undertaken to join the Corum Board following completion of the share placement and after the upcoming 2020 Corum Annual General Meeting.
お知らせ • Nov 03Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020Corum Group Limited announced the appointment of Ms. Eryl Baron as company secretary, effective 3 November 2020. Ms. Baron replaces Mr. Julian Rockett who has been company secretary since 31 August 2020.
お知らせ • Oct 15Corum Group Limited Appoints Jayne Shaw to its Board of DirectorsCorum Group Ltd. announced that Jayne Shaw has accepted an appointment to the Corum Group's Board of Directors. Jayne has significant experience in healthcare management and an experienced clinical background in nursing. Jayne has been a member of a number of private healthcare boards involved with specialist consolidation including cardiology, cancer care, orthopaedics, and women's health and has worked extensively with private equity firms on local and International Healthcare transactions.
お知らせ • Sep 05Corum Group Limited (ASX:COO) completed the acquisition of remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty. Ltd. and Daleflag Pty Ltd.Corum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 million on September 1, 2020. Under the terms of consideration, Corum Group Limited will pay AUD 3.75 million on completion and balance of deferred consideration of AUD 4.15 million to be paid on or before 15 October 2020. Post Completion of the acquisition PharmX will continue to operate as an independent business within the Corum Group in line with its all of market focus. Corum Group launched pro-rata entitlement offer of 1 new Share for every 3 Shares at price of AUD 0.042 per share to raise AUD 5.6 million on September 1, 2020. The proceeds of the Entitlement Offer will be used to partially fund acquisition of the remaining equity and units in PharmX Pty Ltd. Transaction is expected to complete on or before September 4, 2020. The Corum Board expects the acquisition to be earnings per share accretive in its first year. Positive operating cashflow quarterly run rate into FY’21 with acquisition of remaining 57% PharmX interest to further assist. Corum Group Limited (ASX:COO) completed the acquisition of remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty. Ltd. and Daleflag Pty Ltd on September 4, 2020.
お知らせ • Sep 01+ 1 more updateCorum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 millionCorum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 million on September 1, 2020. Under the terms of consideration, Corum Group Limited will pay AUD 3.75 million on completion and balance of deferred consideration of AUD 4.15 million to be paid on or before 15 October 2020. Post Completion of the acquisition PharmX will continue to operate as an independent business within the Corum Group in line with its all of market focus. Corum Group launched pro-rata entitlement offer of 1 new Share for every 3 Shares at price of AUD 0.042 per share to raise AUD 5.6 million on September 1, 2020. The proceeds of the Entitlement Offer will be used to partially fund acquisition of the remaining equity and units in PharmX Pty Ltd. Transaction is expected to complete on or before September 4, 2020. The Corum Board expects the acquisition to be earnings per share accretive in its first year. Positive operating cashflow quarterly run rate into FY’21 with acquisition of remaining 57% PharmX interest to further assist.
お知らせ • Aug 27Corum Group Limited (ASX:COO) completed the acquisition of an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd.Corum Group Limited (ASX:COO) entered into an agreement to acquire an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd for AUD 0.77 million on March 24, 2020. The transaction is expected to be accretive in the first year. Corum Group Limited (ASX:COO) completed the acquisition of an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd on March 31, 2020.